J. Montgomery Keeps Hold on Genta

Analyst Brian Rye says investors should not accumulate shares given the uncertainty surrounding the future of the Genasense program and the company's precarious financial condition

Genta's (GNTA ) multiple myeloma trial fails to meet a primary endpoint. J. Montgomery kept a hold rating on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.